Navigation Links
BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
Date:8/13/2008

ological tolerance with respect to ongoing immune attack as a result of high doses of peptide periodically delivered intravenously. The potential benefit of the drug for any individual patient is therefore expected to be related to the role this peptide plays in that patient's immune system. The degree of immunomodulation achieved will depend on the relationship among the peptide, HLA molecules and T cells.

The results of phase II and long-term follow-up treatment of MS patients with MBP8298 (dirucotide), published in 2006 in the European Journal of Neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to disease progression for five years (versus placebo) in progressive MS patients with HLA types DR2 and/or DR4. Thus, dirucotide (MBP8298), if approved, has the potential to be used as a tailored therapy for patients genetically determined to express the appropriate HLA molecules.

About Multiple Sclerosis

------------------------

Multiple sclerosis (MS) is thought to affect as many as 2.5 million people worldwide, including approximately 75,000 in Canada, 400,000 in the United States and more than 500,000 in Europe. It is a disease that affects more women than men, with onset typically occurring between 20 and 50 years of age. MS is caused by damage to myelin, the protective sheath surrounding nerve fibers in the central nervous system, which interferes with messages from the brain to the body. Symptoms of MS may include vision problems, loss of balance, numbness, difficulty walking and paralysis. Approximately 40 percent of all MS patients have the secondary progressive form of the disease.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMS Medical Announces Second Quarter 2008 Results
2. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
3. BioMS Medical to present at BMO Healthcare Conference
4. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. BioMS Medical to present at Jefferies Healthcare Conference
6. BioMS Medical to present at 2008 BIO International Convention
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medical announces first quarter 2008 results
9. BioMs Medical to present at TIDES(R) Conference
10. BioMS Medical to present at Rodman and Renshaw Global Healthcare Conference
11. BioMS Medical Provides Update On Pipeline Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... (PRWEB) July 28, 2014 According ... Transparency Market Research "Regenerative Medicine (Bone and Joint) ... and Tissue Engineering; By Applications - Bone Graft ... Others) - Global Industry Analysis, Size, Share, Growth, ... regenerative medicine (bone and joint) market was valued ...
(Date:7/28/2014)... , July 28, 2014  David Hardison, ... ConvergeHEALTH by Deloitte , has been elected chairman ... Standards Consortium, a non-profit working to establish common ... particularly as it relates to electronic health records. ... CDISC,s mission of collaborating with organizations across the ...
(Date:7/28/2014)... July 28, 2014 The global market ... by 2020, according to a new study by Grand ... rising demand for effective vaccines and drugs in an ... medical needs is expected to drive market demand over ... enhance agricultural productivity via the use of genetically engineered ...
(Date:7/26/2014)... 26, 2014 Canada Endoscopy Visualization ... data on the Canada Endoscopy Visualization Systems market. ... dollars, volume (in units) and average prices (in ... Visualization Systems, Mid-Range Endoscopy Visualization Systems and Low-End ... http://www.marketresearchreports.biz/analysis/213254 . , The report also provides ...
Breaking Biology Technology:Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5
... March 14, 2011 Argentum Medical, LLC today issued a ... versus Noble Biomaterials, Inc. "The most important thing ... patents and it is business as usual for Argentum," said ... case concerned non-patent issues and is currently being appealed. We ...
... Biofuels, a bioenergy crop company using breeding and biotechnology ... it is applying more than 1.6 million genetic markers ... of marker assisted selection (MAS) methods to produce elite, ... the announcement during its presentation at the Biowise 2011 ...
... March 11, 2011 /PRNewswire-Asia-FirstCall/ --Tianyin Pharmaceutical Co., Inc. (NYSE ... specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, ... at the 23rd ROTH Annual OC Growth Stock Conference ... Carlton in Dana Point, California. Dr. James ...
Cached Biology Technology:Argentum Medical Issues Response to Recent Decision in Litigation With Noble Biomaterials 2SG Biofuels Advances Jatropha Biotech Platform with Application of Genetic Markers to Reference Genome 2TPI Attends 23rd ROTH Annual OC Growth Stock Conference from March 13-16, 2011 2
(Date:7/28/2014)... Roald Amundsen became the first man to reach the ... years later, an international team of scientists led by ... proven that air pollution from industrial activities arrived long ... from widely spaced locations around the Antarctic continent, including ... and precise reconstruction to date of lead pollution over ...
(Date:7/27/2014)... asteroid strike that wiped them out if it had ... say. , A fresh study using up-to-date fossil records ... a new narrative of the prehistoric creatures, demise, some ... the few million years before a 10km-wide asteroid struck ... This included extensive volcanic activity, changing sea levels and ...
(Date:7/27/2014)... discovered a new species of mayfly in the southern Western ... In fact, this is the first time that any mayfly ... in peninsular India. , The new species, called Labiobaetis ... for his substantial contribution to the understanding of the Ephemeroptera ... a study that describes the new mayfly in the ...
Breaking Biology News(10 mins):Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3Dinosaurs fell victim to perfect storm of events, study shows 2
... by researchers at Baylor College of Medicine (BCM) and ... DNA sequencing to the patient's bedside, the doctor's office ... battlefield. , "We could eventually do direct detection of ... performed in the laboratory, said Dr. Michael L. Metzker, ...
... in the March 30th edition of the prestigious scientific journal ... UK's national academy of science) shows that the transfer of ... is much larger and more extensive than previously believed. , ... in a contentious debate. It is the first to isolate ...
... "A Method of Reconstituting Nucleic Acid Molecules" today to ... of DermaPlus, Inc. The patent covers methods for recovering ... allow scientists to reassemble everything from prehistoric, extinct animals ... applied by our scientists, brings us closer to our ...
Cached Biology News:Color-blind method opens new doors in DNA sequencing 2Color-blind method opens new doors in DNA sequencing 3Researchers reveal the infectious impact of salmon farms on wild salmon 2Researchers reveal the infectious impact of salmon farms on wild salmon 3Researchers reveal the infectious impact of salmon farms on wild salmon 4Dinosaur DNA? New Patent Covers Degraded DNA recovery 2
Kit includes your choice of reagents for labeling 3 x 10 9 cells and EasySep magnet....
... the efficient enrichment of functional endoplasmic ... cell culture. The isolated ER are ... metabolic pathway analysis. Metabolic abnornalities of ... children, cystic fibrosis and many more ...
... for stabilizing 50g of purified RNA samples for ... delivers all of the advantages and applications you ... the RNA can be used for enzymatic applications ... has been optimised for the stabilization of aqueous ...
Human SEAP ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
Biology Products: